194 related articles for article (PubMed ID: 16800959)
21. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
Becerra E; De La Torre I; Leandro MJ; Cambridge G
Clin Exp Immunol; 2017 Dec; 190(3):372-383. PubMed ID: 28800164
[TBL] [Abstract][Full Text] [Related]
22. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation.
Shulga-Morskaya S; Dobles M; Walsh ME; Ng LG; MacKay F; Rao SP; Kalled SL; Scott ML
J Immunol; 2004 Aug; 173(4):2331-41. PubMed ID: 15294946
[TBL] [Abstract][Full Text] [Related]
23. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors.
Zhang X; Park CS; Yoon SO; Li L; Hsu YM; Ambrose C; Choi YS
Int Immunol; 2005 Jun; 17(6):779-88. PubMed ID: 15908449
[TBL] [Abstract][Full Text] [Related]
24. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.
Avery DT; Kalled SL; Ellyard JI; Ambrose C; Bixler SA; Thien M; Brink R; Mackay F; Hodgkin PD; Tangye SG
J Clin Invest; 2003 Jul; 112(2):286-97. PubMed ID: 12865416
[TBL] [Abstract][Full Text] [Related]
25. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
[TBL] [Abstract][Full Text] [Related]
26. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].
Valor L; López-Longo FJ
Med Clin (Barc); 2015 Sep; 145(5):206-10. PubMed ID: 25433780
[TBL] [Abstract][Full Text] [Related]
27. TACI attenuates antibody production costimulated by BAFF-R and CD40.
Sakurai D; Kanno Y; Hase H; Kojima H; Okumura K; Kobata T
Eur J Immunol; 2007 Jan; 37(1):110-8. PubMed ID: 17154264
[TBL] [Abstract][Full Text] [Related]
28. BAFF costimulation of Toll-like receptor-activated B-1 cells.
Ng LG; Ng CH; Woehl B; Sutherland AP; Huo J; Xu S; Mackay F; Lam KP
Eur J Immunol; 2006 Jul; 36(7):1837-46. PubMed ID: 16791880
[TBL] [Abstract][Full Text] [Related]
29. Identification of proteoglycans as the APRIL-specific binding partners.
Ingold K; Zumsteg A; Tardivel A; Huard B; Steiner QG; Cachero TG; Qiang F; Gorelik L; Kalled SL; Acha-Orbea H; Rennert PD; Tschopp J; Schneider P
J Exp Med; 2005 May; 201(9):1375-83. PubMed ID: 15851487
[TBL] [Abstract][Full Text] [Related]
30. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
31. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma.
Yang S; Li JY; Xu W
Crit Rev Oncol Hematol; 2014 Aug; 91(2):113-22. PubMed ID: 24629840
[TBL] [Abstract][Full Text] [Related]
32. Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.
Jacob CO; Yu N; Sindhava V; Cancro MP; Pawar RD; Putterman C; Stohl W
Arthritis Rheumatol; 2015 Sep; 67(9):2523-35. PubMed ID: 25989238
[TBL] [Abstract][Full Text] [Related]
33. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
34. The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors.
Shen X; Wang M; Guo Y; Ju S
Adv Clin Exp Med; 2016; 25(5):837-844. PubMed ID: 28028945
[TBL] [Abstract][Full Text] [Related]
35. Reduced BAFF-R and increased TACI expression in common variable immunodeficiency.
Barbosa RR; Silva SL; Silva SP; Melo AC; Pereira-Santos MC; Barata JT; Hammarström L; Cascalho M; Sousa AE
J Clin Immunol; 2014 Jul; 34(5):573-83. PubMed ID: 24809296
[TBL] [Abstract][Full Text] [Related]
36. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract][Full Text] [Related]
37. BLyS and B cell homeostasis.
Woodland RT; Schmidt MR; Thompson CB
Semin Immunol; 2006 Oct; 18(5):318-26. PubMed ID: 16931037
[TBL] [Abstract][Full Text] [Related]
38. Expression of TNF-α, APRIL and BCMA in Behcet's disease.
Shaker OG; Tawfic SO; El-Tawdy AM; El-Komy MH; El Menyawi M; Heikal AA
J Immunol Res; 2014; 2014():380405. PubMed ID: 25759827
[TBL] [Abstract][Full Text] [Related]
39. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells.
Ng LG; Sutherland AP; Newton R; Qian F; Cachero TG; Scott ML; Thompson JS; Wheway J; Chtanova T; Groom J; Sutton IJ; Xin C; Tangye SG; Kalled SL; Mackay F; Mackay CR
J Immunol; 2004 Jul; 173(2):807-17. PubMed ID: 15240667
[TBL] [Abstract][Full Text] [Related]
40. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
